Brand Name
Ga-68 PSMA-11
Generic Name
Ga-68 Gozetotide
View Brand Information FDA approval date: December 09, 2020
Classification: Radioactive Diagnostic Agent
Form: Injection
What is Ga-68 PSMA-11 (Ga-68 Gozetotide)?
Gallium Ga 68 Gozetotide Injection is indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen level. Gallium Ga 68 Gozetotide Injection is a radioactive diagnostic agent indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen level.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
GA-68 PSMA-11 PET To Evaluate Malignant Glioma Recurrence - A Pilot Study
Summary: This clinical trial evaluates whether gallium-68 (Ga-68) prostate specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) imaging is useful in differentiating between disease that has come back after a period of improvement (recurrence) or that is growing, spreading, or getting worse (progression) and treatment effect in patients with glioma. Patients with g...